Petrelintide 2766385-23-1, also known as ZP8396, is an investigational long-acting peptide developed for obesity and weight-management research. Developed by Zealand Pharma and advanced through collaboration with Roche, this peptide has gained attention for its potential to regulate appetite, improve satiety, and support body-weight reduction.
What Is Petrelintide?
Petrelintide is a synthetic human amylin analogue designed to mimic the activity of the naturally occurring hormone amylin. Amylin is released by pancreatic beta cells alongside insulin and plays an important role in appetite regulation, food intake, and metabolic processes. Its long-acting properties make petrelintide a promising candidate for once-weekly administration.
.jpg)
Mechanism of Action
Petrelintide 2766385-23-1 works by targeting amylin-related receptor pathways involved in appetite and satiety regulation. Its activity helps promote feelings of fullness and reduce food consumption. Unlike conventional GLP-1 receptor agonists, petrelintide follows an amylin-based mechanism, offering an alternative approach to metabolic and obesity research.
Potential Research
Applications
- Obesity and weight-management research.
- Appetite and satiety regulation.
- Amylin receptor pharmacology.
- Metabolic health investigations.
- Development of combination peptide therapies.
Conclusion
Petrelintide
2766385-23-1 represents an important advancement in amylin-based peptide
research. Its long-acting profile, distinct mechanism of action, and
encouraging clinical findings make it a promising candidate for future obesity
treatments. However, it remains investigational and requires further clinical
evaluation to establish its long-term safety and effectiveness.
Follow our Facebook and Twitter for more information about our product.
